We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. FibroBiologics, Inc. (NASDAQ:FBLG) is among the most popular penny stocks.
TheFly reported on May 22 that FBLG released preclinical findings from its CYPS317 psoriasis program at the Society for Investigative Dermatology 2026 Annual Meeting. The company reported that its fibroblast spheroid therapy reduced disease severity in psoriasis mouse models while showing a stronger systemic safety profile compared to single-cell approaches.
Additional results demonstrated sustained therapeutic activity with booster dosing, including reductions in PASI scores, lower immune cell accumulation, and protection against skin thickening and inflammatory infiltration. FBLG stated that the data support CYPS317’s potential as a targeted immunomodulatory treatment approach for chronic psoriasis without broad immune suppression.
Separately, earlier on May 11, FibroBiologics, Inc. (NASDAQ:FBLG) broadened the scope of its fibroblast therapeutic platform to include Hantavirus pulmonary syndrome, a severe respiratory disease ******* ociated with high mortality rates. The company stated that the expansion builds on prior preclinical research involving acute respiratory distress syndrome, where fibroblasts demonstrated potential to reduce inflammatory signaling, repair tissue damage, and improve endothelial barrier function.
FBLG believes the similarities between HPS-related lung injury and ARDS make its fibroblast-based approach suitable for further investigation in Hantavirus models. The company is currently ******* sing the platform’s impact on cytokine activity, vascular permeability, and respiratory tissue damage while exploring future regulatory discussions.
TheFly reported on May 22 that FBLG released preclinical findings from its CYPS317 psoriasis program at the Society for Investigative Dermatology 2026 Annual Meeting. The company reported that its fibroblast spheroid therapy reduced disease severity in psoriasis mouse models while showing a stronger systemic safety profile compared to single-cell approaches.
Additional results demonstrated sustained therapeutic activity with booster dosing, including reductions in PASI scores, lower immune cell accumulation, and protection against skin thickening and inflammatory infiltration. FBLG stated that the data support CYPS317’s potential as a targeted immunomodulatory treatment approach for chronic psoriasis without broad immune suppression.
Separately, earlier on May 11, FibroBiologics, Inc. (NASDAQ:FBLG) broadened the scope of its fibroblast therapeutic platform to include Hantavirus pulmonary syndrome, a severe respiratory disease ******* ociated with high mortality rates. The company stated that the expansion builds on prior preclinical research involving acute respiratory distress syndrome, where fibroblasts demonstrated potential to reduce inflammatory signaling, repair tissue damage, and improve endothelial barrier function.
FBLG believes the similarities between HPS-related lung injury and ARDS make its fibroblast-based approach suitable for further investigation in Hantavirus models. The company is currently ******* sing the platform’s impact on cytokine activity, vascular permeability, and respiratory tissue damage while exploring future regulatory discussions.
21 hours ago
